Mentions
Extended reach
Total likes
Video views
AI synopsis
Discussions exemplify strong agreement as many posts highlight the significant reduction in all-cause mortality with semaglutide, using phrases like 'incredible' and 'game-changing.' They show high interest by referencing detailed study results and implications, such as fewer infection-related deaths, and deeply engage with scientific data and potential impacts on treatment practices, making it clear that the publication's findings could have substantial clinical and societal effects.
Most discussions support the positive effects of semaglutide on reducing mortality, highlighting studies and data that endorse its benefits, indicating strong agreement with the publication.
The discussions are highly engaged, referencing specific trials, statistics, and detailed implications, demonstrating a keen interest in the research findings.
Participants actively analyze the study, referencing related works, offering insights, and debating mechanisms, showing deep involvement beyond surface-level reactions.
The conversations suggest the research could influence clinical practices and public health policies, emphasizing the significance of semaglutide's potential to reduce deaths, especially from COVID-19 and cardiovascular causes.
Semaglutide significantly reduces the risk of all-cause mortality and COVID-19–related deaths. https://t.co/gXm06h8WE9 https://t.co/QRTyP3qqp0
GLP1 #semaglutide: Reduces death even with infections like #COVID19 in patients with #CVD and #obesity https://t.co/uAhDWdUj3G #JACC #Semaglutide https://t.co/7Ht3Kly1t0
New study found that ozempic reduced all-cause mortality by 19% over 4 years and that "the reduction in CV death, MI, and ischemic stroke with semaglutide in SELECT does not appear to have been mediated through weight loss." https://t.co/Vbk2E2mNJN https://t.co/0JuEZJjdI4
The Effect of Semaglutide on Mortality and COVID-19–Related Deaths: An Analysis From the SELECT Trial https://t.co/UKW3xKJ5WY https://t.co/5oiU3fOeHX
Une nouvelle analyse d’un essai clinique sur le sémaglutide — l’ingrédient actif de Wegovy — a montré que le médicament de perte de poids populaire réduisait le risque de décès du Covid-19 chez les patients atteints d’une maladie cardiaque. https://t.co/bTlgD1Puyk
The SELECT trial reveals that semaglutide significantly lowers severe COVID events and noncardiovascular deaths in obese patients with cardiovascular disease, highlighting its potential for enhancing overall health…
This video covers recent developments in evolutionary biology and public health, including the health benefits of Ozempic, environmental roles of bats, and potential COVID-19 cures. It highlights the importance of…
Really. pubmed.ncbi.nlm.nih.gov/39217559/
The SELECT trial shows Semaglutide may reduce COVID-19 related deaths. More research needed to confirm. #COVID19 #Semaglutide #HealthResearch https://t.co/lmQrs2RUKd https://t.co/4EkuULv6op
@nevercompIy @TKoala32 @LeadingReport We could also suggest OZEMIC https://t.co/Q9bz2soIzL
RT @acorderofort:
RT @acorderofort:
RT @acorderofort:
RT @jasonwasfy: The Effect of Semaglutide on Mortality and COVID-19-Related Deaths: An Analysis From the SELECT Trial https://t.co/WyiMzMxY…
RT @jasonwasfy: The Effect of Semaglutide on Mortality and COVID-19-Related Deaths: An Analysis From the SELECT Trial https://t.co/WyiMzMxY…
The Effect of Semaglutide on Mortality and COVID-19-Related Deaths: An Analysis From the SELECT Trial https://t.co/WyiMzMxYKS @JACCJournals @MassGenBrigham @TIMIStudyGroup
(8/11) Lastly, Dr. Ben Scirica, @MassGenBrigham, published a secondary analysis of SELECT and found that patients treated with #semaglutide unexpectedly had lower rates of death due to #COVID19, despite similar infection rates: https://t.co/Y0QytBxYQL #JACC https://t.co/EniWh8X5gz
@Allen_Lutz @ChaoticSalsa https://t.co/81krJ42sbG and this seems pertinent as well
RT @SamuelBHume: 10/10 In patients with obesity and heart disease, GLP1 receptor agonism boosted life expectancy - this was partly due to…
@ideafaktory @thomaschattwill And why haven't these shown up in any clinical trials? Besides, when we study all-cause mortality (literally just tracking how people do across all dimensions), the people taking it do better. https://t.co/yhh75Y912D).
The Effect of Semaglutide on Mortality and COVID-19–Related Deaths: An Analysis From the SELECT Trial | Journal of the American College of Cardiology https://t.co/8WMVUFVng0
RT @CristobMorales: https://t.co/7oSUd1QUpd semaglutide 2.4 had lower rates of all-cause death, driven similarly by CV and non-CV death. Th…
RT @CristobMorales: https://t.co/7oSUd1QUpd semaglutide 2.4 had lower rates of all-cause death, driven similarly by CV and non-CV death. Th…
RT @CristobMorales: https://t.co/7oSUd1QUpd semaglutide 2.4 had lower rates of all-cause death, driven similarly by CV and non-CV death. Th…
RT @CristobMorales: https://t.co/7oSUd1QUpd semaglutide 2.4 had lower rates of all-cause death, driven similarly by CV and non-CV death. Th…
RT @CristobMorales: https://t.co/7oSUd1QUpd semaglutide 2.4 had lower rates of all-cause death, driven similarly by CV and non-CV death. Th…
https://t.co/7oSUd1QUpd semaglutide 2.4 had lower rates of all-cause death, driven similarly by CV and non-CV death. The lower rate of non-CV death with semaglutide was predominantly because of fewer infectious deaths. These findings highlight the effect of semaglutide on https://t.co/2d0CCd4tk3
RT @drbennisahmed: The Effect of Semaglutide on Mortality and COVID-19–Related Deaths: An Analysis From the SELECT Trial patients treated…
RT @JACCJournals: GLP1 #semaglutide: Reduces death even with infections like #COVID19 in patients with #CVD and #obesity https://t.co/uAhDW…
The Effect of Semaglutide on Mortality and COVID-19–Related Deaths: An Analysis From the SELECT Trial patients treated with semaglutide 2.4 mg had lower rates of all-cause death, driven similarly by CV and non-CV death https://t.co/k3oWyjLvkg https://t.co/GH9Z1V8Y0y
GLP1 #semaglutide: Reduces death even with infections like #COVID19 in patients with #CVD and #obesity https://t.co/uAhDWdUj3G #JACC #Semaglutide https://t.co/7Ht3Kly1t0
The Effect of Semaglutide on Mortality and COVID-19-Related Deaths: An Analysis From the SELECT Trial. https://t.co/6Mmu4Rnqkv
@NaphiSoc You are absolutely correct that obesity was/is a huge risk for COVID outcomes…but amazingly, it turns out that GLP1s improved outcomes! https://t.co/XQThJS1Lij So we just that we can’t give Covid the “credit”/blame for the obesity statistics that we are discussing.
RT @scottisaacsmd: Semaglutide significantly reduces the risk of all-cause mortality and COVID-19–related deaths. https://t.co/gXm06h8WE9 h…
RT @scottisaacsmd: Semaglutide significantly reduces the risk of all-cause mortality and COVID-19–related deaths. https://t.co/gXm06h8WE9 h…
RT @scottisaacsmd: Semaglutide significantly reduces the risk of all-cause mortality and COVID-19–related deaths. https://t.co/gXm06h8WE9 h…
RT @scottisaacsmd: Semaglutide significantly reduces the risk of all-cause mortality and COVID-19–related deaths. https://t.co/gXm06h8WE9 h…
RT @scottisaacsmd: Semaglutide significantly reduces the risk of all-cause mortality and COVID-19–related deaths. https://t.co/gXm06h8WE9 h…
RT @scottisaacsmd: Semaglutide significantly reduces the risk of all-cause mortality and COVID-19–related deaths. https://t.co/gXm06h8WE9 h…
RT @scottisaacsmd: Semaglutide significantly reduces the risk of all-cause mortality and COVID-19–related deaths. https://t.co/gXm06h8WE9 h…
RT @scottisaacsmd: Semaglutide significantly reduces the risk of all-cause mortality and COVID-19–related deaths. https://t.co/gXm06h8WE9 h…
RT @scottisaacsmd: Semaglutide significantly reduces the risk of all-cause mortality and COVID-19–related deaths. https://t.co/gXm06h8WE9 h…
RT @scottisaacsmd: Semaglutide significantly reduces the risk of all-cause mortality and COVID-19–related deaths. https://t.co/gXm06h8WE9 h…
RT @scottisaacsmd: Semaglutide significantly reduces the risk of all-cause mortality and COVID-19–related deaths. https://t.co/gXm06h8WE9 h…
Semaglutide significantly reduces the risk of all-cause mortality and COVID-19–related deaths. https://t.co/gXm06h8WE9 https://t.co/QRTyP3qqp0
RT @NeuroscienceNew: “The Effect of Semaglutide on Mortality and COVID-19–Related Deaths: An Analysis From the SELECT Trial” by Benjamin M.…
RT @NeuroscienceNew: “The Effect of Semaglutide on Mortality and COVID-19–Related Deaths: An Analysis From the SELECT Trial” by Benjamin M.…
“The Effect of Semaglutide on Mortality and COVID-19–Related Deaths: An Analysis From the SELECT Trial” by Benjamin M. Scirica et al. Journal of the American College of Cardiology https://t.co/Tczrd4tAFJ
Full Study
RT @rogersmcintyre: Very interesting finding that GLP1 Semaglutide Decreases mortality due to COVID-19 infection … perhaps due to the imm…
@venkmurthy @DrMarthaGulati @JAMA_current @JamesADiao @rwyeh @rkwadhera We are also missing a big opportunity to reduce cardiovascular, infectious and all causes mortally through GLP1 drugs as a result of exorbitant prices and artificial shortages https://t.co/Hu1Yw5G7Zf
RT @EricTopol: In the large randomized trial of GLP-1 semaglutide for obesity, there was a significant reduction of all-cause mortality, de…
RT @EricTopol: In the large randomized trial of GLP-1 semaglutide for obesity, there was a significant reduction of all-cause mortality, de…
The Effect of Semaglutide on Mortality and COVID-19–Related Deaths: An Analysis From the SELECT Trial https://t.co/jh9IT4C2Zx
The Effect of Semaglutide on Mortality and COVID-19–Related Deaths: An Analysis From the SELECT Trial
The Effect of Semaglutide on Mortality and COVID-19–Related Deaths: An Analysis From the SELECT Trial "Compared to placebo, patients treated with semaglutide 2.4 mg had lower rates of all-cause death, driven similarly by CV and non-CV death." https://t.co/yzMhk750Rp
The Effect of Semaglutide on Mortality and COVID-19-Related Deaths – An Analysis From the SELECT Trial
The Effect of Semaglutide on Mortality and COVID-19–Related Deaths: An Analysis From the SELECT Trial "Compared to placebo, patients treated with semaglutide 2.4 mg had lower rates of all-cause death, driven similarly by CV and non-CV death." https://t.co/98GC4N8YrG
RT @EricTopol: In the large randomized trial of GLP-1 semaglutide for obesity, there was a significant reduction of all-cause mortality, de…
RT @SamuelBHume: 10/10 In patients with obesity and heart disease, GLP1 receptor agonism boosted life expectancy - this was partly due to…
заболевших реже возникали серьезные нежелательные осложнения связанные с коронавирусной инфекцией [читаешь и думаешь, что это чуть ли не святая вода]. Источник: https://t.co/5YqOy3o641 Клинический психоанализ
RT @SamuelBHume: 10/10 In patients with obesity and heart disease, GLP1 receptor agonism boosted life expectancy - this was partly due to…
10/10 In patients with obesity and heart disease, GLP1 receptor agonism boosted life expectancy - this was partly due to reduced Covid-related deaths https://t.co/NruU0QRs4K https://t.co/JibfRuhUek
The Effect of Semaglutide on Mortality and COVID-19–Related Deaths: An Analysis From the SELECT Trial | Journal of the American College of Cardiology https://t.co/ebITcGqgCp
The Effect of Semaglutide on Mortality and COVID-19–Related Deaths: An Analysis From the SELECT Trial | Journal of the American College of Cardiology https://t.co/ZzCPh8ViTp
RT @svrnco: New study found that ozempic reduced all-cause mortality by 19% over 4 years and that "the reduction in CV death, MI, and ische…
The Effect of Semaglutide on Mortality and COVID-19–Related Deaths: An Analysis From the SELECT Trial | Journal of the American College of Cardiology https://t.co/6JAeOrfINO
RT @laurenceide69: Une nouvelle analyse d’un essai clinique sur le sémaglutide — l’ingrédient actif de Wegovy — a montré que le médicament…
Une nouvelle analyse d’un essai clinique sur le sémaglutide — l’ingrédient actif de Wegovy — a montré que le médicament de perte de poids populaire réduisait le risque de décès du Covid-19 chez les patients atteints d’une maladie cardiaque. https://t.co/bTlgD1Puyk
RT @carpe_diem0820: The Effect of Semaglutide on Mortality and COVID-19–Related Deaths: An Analysis From the SELECT Trial… https://t.co/UKW…
https://t.co/O9HyVuTiqB  
RT @carpe_diem0820: The Effect of Semaglutide on Mortality and COVID-19–Related Deaths: An Analysis From the SELECT Trial… https://t.co/UKW…
RT @carpe_diem0820: The Effect of Semaglutide on Mortality and COVID-19–Related Deaths: An Analysis From the SELECT Trial… https://t.co/UKW…
The Effect of Semaglutide on Mortality and COVID-19–Related Deaths: An Analysis From the SELECT Trial https://t.co/UKW3xKJ5WY https://t.co/5oiU3fOeHX
RT @DanielGriffinMD: The Effect of Semaglutide on Mortality and COVID-19–Related Deaths: An Analysis From the SELECT Trial | Journal of the…
@sassistheword Oh, and also: https://t.co/3FBP73Qt3f
@agraybee Years and years of attempts at using this approach in the general population has never shown this kind of success. Link: https://t.co/3FBP73Qt3f https://t.co/jyDGEJAF85
The Effect of Semaglutide on Mortality and COVID-19–Related Deaths: An Analysis From the SELECT Trial | Journal of the American College of Cardiology https://t.co/aOswCIOFmV
This study found that #semaglutide 2.4 mg reduced all-cause and #cardiovascular deaths, including fewer infection-related deaths, in #obese patients with cardiovascular disease. @JACCJournals By @LincoffMichael, @IldikoLingvay, @weekepe, @swiviott, et al. https://t.co/TZ871YfRgx https://t.co/txvM7a6lVF
RT @EricTopol: In the large randomized trial of GLP-1 semaglutide for obesity, there was a significant reduction of all-cause mortality, de…
@ArsonAtDennys @SamtheNightOwl in a long term study (obese non-diabetics w/ CV risk factors) semaglutide reduced morbidity and mortality across all causes of death. the study got additional media coverage bc it also reduced risk of death from covid compared to placebo https://t.co/1OeKaOGmVN
@poetricus2 https://t.co/wqBpbofeaL DEP https://t.co/UxBVqrFDe5
RT @svrnco: New study found that ozempic reduced all-cause mortality by 19% over 4 years and that "the reduction in CV death, MI, and ische…
New study found that ozempic reduced all-cause mortality by 19% over 4 years and that "the reduction in CV death, MI, and ischemic stroke with semaglutide in SELECT does not appear to have been mediated through weight loss." https://t.co/Vbk2E2mNJN https://t.co/0JuEZJjdI4
元論文はこちら The Effect of Semaglutide on Mortality and COVID-19–Related Deaths: An Analysis From the SELECT Trial | Journal of the American College of Cardiology https://t.co/ybtiYbiqx0
@John_Stepek Ha! I said similar in a group chat when this came up yesterday. There’s a study doing the rounds about how semaglutide reduces COVID mortality but the reason is inconclusive so far: https://t.co/L7KAN9T8ym
RT @EricTopol: In the large randomized trial of GLP-1 semaglutide for obesity, there was a significant reduction of all-cause mortality, de…
RT @EricTopol: In the large randomized trial of GLP-1 semaglutide for obesity, there was a significant reduction of all-cause mortality, de…
@AliceFromQueens @pauliebeats183 I mean…. https://t.co/yBPu24YyrH).
A trial study has found that injections of the #weightloss drug #Wegovy reduced the risk of #deaths from #COVID19 by about a third while also significantly reducing risk of death from #cardiovasculardisease or any other cause. https://t.co/JpGy2Cwzux https://t.co/2YPWaSH3jA
RT @EricTopol: In the large randomized trial of GLP-1 semaglutide for obesity, there was a significant reduction of all-cause mortality, de…
RT @EricTopol: In the large randomized trial of GLP-1 semaglutide for obesity, there was a significant reduction of all-cause mortality, de…
RT @CMichaelGibson: #Semaglutide lowers Mortality and COVID-19–Related Deaths: An Analysis From the SELECT Trial | Journal of the American…
@pauliebeats183 Cool. My Cash App link is in my bio. You’ve been very nice and reasonable about this. So I feel a bit guilty breaking the news that the study you doubted could happen was pubbed on August 30th and the significance is way beyond. You owe me $50. https://t.co/n1W6rU9nsu
RT @EricTopol: In the large randomized trial of GLP-1 semaglutide for obesity, there was a significant reduction of all-cause mortality, de…
RT @EricTopol: In the large randomized trial of GLP-1 semaglutide for obesity, there was a significant reduction of all-cause mortality, de…
RT @EricTopol: In the large randomized trial of GLP-1 semaglutide for obesity, there was a significant reduction of all-cause mortality, de…
RT @EricTopol: In the large randomized trial of GLP-1 semaglutide for obesity, there was a significant reduction of all-cause mortality, de…
RT @CMichaelGibson: #Semaglutide lowers Mortality and COVID-19–Related Deaths: An Analysis From the SELECT Trial | Journal of the American…
RT @EricTopol: In the large randomized trial of GLP-1 semaglutide for obesity, there was a significant reduction of all-cause mortality, de…
RT @EricTopol: In the large randomized trial of GLP-1 semaglutide for obesity, there was a significant reduction of all-cause mortality, de…
RT @EricTopol: In the large randomized trial of GLP-1 semaglutide for obesity, there was a significant reduction of all-cause mortality, de…
RT @EricTopol: In the large randomized trial of GLP-1 semaglutide for obesity, there was a significant reduction of all-cause mortality, de…
RT @CMichaelGibson: #Semaglutide lowers Mortality and COVID-19–Related Deaths: An Analysis From the SELECT Trial | Journal of the American…
@ClickingSeason https://t.co/n1W6rU9Vi2
@notanastronomer A hazard ratio of 0.81 is fairly incredible. https://t.co/z9NzpwFaCK
RT @Kiyohime_Okami: 肥満に対するGLP-1セマグルチド(リベルサス)の大規模試験で全死亡率、新型コロナ死亡、新型コロナの重篤な有害事象が大幅に減少。図1 JACC 2024年8月30日 https://t.co/mpajuEYMSH… https://t.…
RT @EricTopol: In the large randomized trial of GLP-1 semaglutide for obesity, there was a significant reduction of all-cause mortality, de…
RT @CMichaelGibson: #Semaglutide lowers Mortality and COVID-19–Related Deaths: An Analysis From the SELECT Trial | Journal of the American…
RT @EricTopol: In the large randomized trial of GLP-1 semaglutide for obesity, there was a significant reduction of all-cause mortality, de…
RT @AndrewW66619812: The study in the "Journal of the American College of Cardiology" the above "Guardian" article is based upon: “The Eff…
The study in the "Journal of the American College of Cardiology" the above "Guardian" article is based upon: “The Effect of Semaglutide on Mortality and COVID-19–Related Deaths: An Analysis From the SELECT Trial” 2/2 https://t.co/bgPb1nSr7v
RT @EricTopol: In the large randomized trial of GLP-1 semaglutide for obesity, there was a significant reduction of all-cause mortality, de…
RT @CMichaelGibson: #Semaglutide lowers Mortality and COVID-19–Related Deaths: An Analysis From the SELECT Trial | Journal of the American…
RT @EricTopol: In the large randomized trial of GLP-1 semaglutide for obesity, there was a significant reduction of all-cause mortality, de…
RT @CMichaelGibson: #Semaglutide lowers Mortality and COVID-19–Related Deaths: An Analysis From the SELECT Trial | Journal of the American…
The Effect of Semaglutide on Mortality and COVID-19–Related Deaths: An Analysis From the SELECT Trial | Journal of the American College of Cardiology https://t.co/4YV1eMKfDx
RT @CMichaelGibson: #Semaglutide lowers Mortality and COVID-19–Related Deaths: An Analysis From the SELECT Trial | Journal of the American…
RT @EricTopol: In the large randomized trial of GLP-1 semaglutide for obesity, there was a significant reduction of all-cause mortality, de…
RT @EricTopol: In the large randomized trial of GLP-1 semaglutide for obesity, there was a significant reduction of all-cause mortality, de…
RT @EricTopol: In the large randomized trial of GLP-1 semaglutide for obesity, there was a significant reduction of all-cause mortality, de…
RT @EricTopol: In the large randomized trial of GLP-1 semaglutide for obesity, there was a significant reduction of all-cause mortality, de…
RT @CMichaelGibson: #Semaglutide lowers Mortality and COVID-19–Related Deaths: An Analysis From the SELECT Trial | Journal of the American…
RT @hmkyale: 1/7 Amazing research in @JACCJournals explores effect of semaglutide on mortality and #COVID19 outcomes in people with overwei…
10/10 Arkadaşlar obezite tedavi edilmesi gereken bir hastalıktır. Zayıflama ilacına karşı olan hekimler de var. Dün yayınlanan şu büyük çalışma hekimlerin bu ilaçlar konusundaki şüphelerini gidermek açısından çok önemli.. https://t.co/L9rcYGQkj7 https://t.co/QYKLNGxFMf
RT @EricTopol: In the large randomized trial of GLP-1 semaglutide for obesity, there was a significant reduction of all-cause mortality, de…
RT @EricTopol: In the large randomized trial of GLP-1 semaglutide for obesity, there was a significant reduction of all-cause mortality, de…
RT @EricTopol: In the large randomized trial of GLP-1 semaglutide for obesity, there was a significant reduction of all-cause mortality, de…
Dün yayınlanan ve 17,604 kişinin incelendiği büyük bir çalışmanın sonuçlarına göre, aşırı kilolu veya obez kişilerde Semaglutide tüm sebeplere bağlı ölümleri azaltıyor: https://t.co/L9rcYGQkj7 https://t.co/Mq6U4jIHYs
RT @EricTopol: In the large randomized trial of GLP-1 semaglutide for obesity, there was a significant reduction of all-cause mortality, de…
RT @EricTopol: In the large randomized trial of GLP-1 semaglutide for obesity, there was a significant reduction of all-cause mortality, de…
The Effect of Semaglutide on Mortality and COVID-19–Related Deaths: An Analysis From the SELECT Trial A recent international study led by Brigham and Women’s Hospital researchers has shown that #semaglutide injections significantly reduce mortality rates from various causes, https://t.co/waWOjy1cb0
The Effect of Semaglutide on Mortality and COVID-19–Related Deaths: An Analysis From the SELECT Trial | Journal of the American College of Cardiology https://t.co/kfN3BW3kVq
Wegovy scheint ein Alleskönner zu sein, nach dieser Studie reduziert es bei Adipositas auch die Sterblichkeit an Covid-19 The Effect of Semaglutide on Mortality and COVID-19–Related Deaths: An Analysis From the SELECT Trial https://t.co/XmbYIF0hIa
The Effect of Semaglutide on Mortality and COVID-19–Related Deaths: An Analysis From the SELECT Trial semaglutide 2.4 mg had lower rates of all-cause death, driven similarly by CV and non-CV death https://t.co/k3oWyjM39O https://t.co/04vb5926r0
The Effect of Semaglutide on Mortality and COVID-19–Related Deaths: An Analysis From the SELECT Trial | Journal of the American College of Cardiology https://t.co/o5cJRzCaHJ
Full text in JACC https://www.jacc.org/doi/10.1016/j.jacc.2024.08.007
RT @TIMIStudyGroup: Dr. Ben Scirica will speak on the effect of semaglutide on mortality and COVID-19-related deaths in a pre-specified ana…
Dr. Ben Scirica will speak on the effect of semaglutide on mortality and COVID-19-related deaths in a pre-specified analysis from the SELECT trial, in 24 hrs in Warsaw #ESCCongress
doi:10. doi:10.1016/j.jacc.2011.08.026 1007/s00401-023-02669-8 17 ... doi:10.1016/j.nmd.2024.08.007. Disord NMD 2001;11(6-7):525-529. doi:10.1016 ...
3235, 2024 10.1016/j.ekir.2024.08.007 PubMed between dialysate bicarbonate concentration and all-cause mortality ... 2010 10.1016/j.jacc.2009.07.068 PubMed ...
J. Am. Coll. Cardiol. 84, 1632–1642. https://doi.org/10.1016/j.jacc.2024.08.007. shift in the treatment of obesity and diabetes, offering substantial
https://www.jacc.org/doi/10.1016/j.jacc.2024.08.007 https://www.medpagetoday. com/meetingcoverage/esc/111720 https://www.nytimes. com ...
https://www.jacc.org/doi/10.1016/j.jacc.2024.08.007 https://www.medpagetoday. com/meetingcoverage/esc/111720 https://www.nytimes. com ...
https://www.jacc.org/doi/10.1016/j.jacc.2024.08.007 https://www.medpagetoday. com/meetingcoverage/esc/111720 https://www.nytimes. com ...
... (JACC, 2024). No photo description available. Amro Alhadi ... https://www.jacc.org/doi/10.1016/j.jacc.2024.08.007 https://www.medpagetoday.
Fincerone, böbreği korumak için kullanılan bir nonsteroidal mineralokortikoid reseptör antagonistisidir.
https://www.jacc.org/doi/10.1016/j.jchf. 2024.08.007?utm_medium=social&utm_source=twitt er_post&utm_campaign=twitter_post #CardioEd # ...
https://www.jacc.org/doi/10.1016/j.jchf. 2024.08.007?utm_medium=social&utm_source=twitt er_post&utm_campaign=twitter_post #CardioEd # ...
2024;doi:10.1016/j.jacc.2024.08.007. Disclosures: Ryan reports advising for AbbVie, Altimmune, Amgen, AstraZeneca, Boehringer Ingelheim, ...
https://www.jacc.org/doi/10.1016/j.jchf. 2024.08.007?utm_medium=social&utm_source=twitt er_post&utm_campaign=twitter_post #CardioEd # ...
https://www.jacc.org/doi/10.1016/j.jacc.2024.08.007 https://www.medpagetoday. com/meetingcoverage/esc/111720 https://www.nytimes. com ...
https://www.jacc.org/doi/10.1016/j.jacc.2024.08.007 https://www.medpagetoday. com/meetingcoverage/esc/111720 https://www.nytimes. com ...
https://www.jacc.org/doi/10.1016/j.jchf. 2024.08.007?utm_medium=social&utm_source=twitt er_post&utm_campaign=twitter_post #CardioEd ...
https://www.jacc.org/doi/10.1016/j.jchf. 2024.08.007?utm_medium=social&utm_source=twitt er_post&utm_campaign=twitter_post #CardioEd # ...
https://www.jacc.org/doi/10.1016/j.jchf. 2024.08.007?utm_medium=social&utm_source=twitt er_post&utm_campaign=twitter_post #CardioEd ...
... (JACC, 2024). No photo description available. Amro Alhadi ... https://www.jacc.org/doi/10.1016/j.jacc.2024.08.007 https://www.medpagetoday.
https://www.jacc.org/doi/10.1016/j.jchf. 2024.08.007?utm_medium=social&utm_source=twitt er_post&utm_campaign=twitter_post #CardioEd ...
https://www.jacc.org/doi/10.1016/j.jchf. 2024.08.007?utm_medium=social&utm_source=twitt er_post&utm_campaign=twitter_post #CardioEd ...
https://www.jacc.org/doi/10.1016/j.jchf. 2024.08.007?utm_medium=social&utm_source=twitt er_post&utm_campaign=twitter_post #CardioEd ...
https://www.jacc.org/doi/10.1016/j.jacc.2024.08.007 https://www.medpagetoday. com/meetingcoverage/esc/111720 https://www.nytimes. com ...
https://www.jacc.org/doi/10.1016/j.jacc.2024.08.007 https://www.medpagetoday. com/meetingcoverage/esc/111720 https://www.nytimes. com ...
https://www.jacc.org/doi/10.1016/j.jchf. 2024.08.007?utm_medium=social&utm_source=twitt er_post&utm_campaign=twitter_post #CardioEd # ...
... (JACC, 2024). No photo description available. Amro Alhadi ... https://www.jacc.org/doi/10.1016/j.jacc.2024.08.007 https://www.medpagetoday.
https://www.jacc.org/doi/10.1016/j.jchf. 2024.08.007?utm_medium=social&utm_source=twitt er_post&utm_campaign=twitter_post #CardioEd # ...
Mar 17, 2025. Epublished DOI: 10.1016/j.jacc. 2025.02.018.
https://www.jacc.org/doi/10.1016/j.jchf. 2024.08.007?utm_medium=social&utm_source=twitt er_post&utm_campaign=twitter_post #CardioEd # ...
https://www.jacc.org/doi/10.1016/j.jchf. 2024.08.007?utm_medium=social&utm_source=twitt er_post&utm_campaign=twitter_post #CardioEd # ...
https://www.jacc.org/doi/10.1016/j.jchf. 2024.08.007?utm_medium=social&utm_source=twitt er_post&utm_campaign=twitter_post #CardioEd # ...
https://www.jacc.org/doi/10.1016/j.jchf. 2024.08.007?utm_medium=social&utm_source=twitt er_post&utm_campaign=twitter_post #CardioEd # ...
https://www.jacc.org/doi/10.1016/j.jchf. 2024.08.007?utm_medium=social&utm_source=twitt er_post&utm_campaign=twitter_post #CardioEd # ...
https://www.jacc.org/doi/10.1016/j.jchf. 2024.08.007?utm_medium=social&utm_source=twitt er_post&utm_campaign=twitter_post #CardioEd ...
https://www.jacc.org/doi/10.1016/j.jchf. 2024.08.007?utm_medium=social&utm_source=twitte r_post&utm_campaign=twitter_post #CardioEd ...
https://www.jacc.org/doi/10.1016/j.jchf. 2024.08.007?utm_medium=social&utm_source=twitt er_post&utm_campaign=twitter_post #CardioEd ...
141 likes, 1 comments - prof.dr.huseyinoflaz on December 14, 2024: "#aort".
https://www.jacc.org/doi/10.1016/j.jchf. 2024.08.007?utm_medium=social&utm_source=twitt er_post&utm_campaign=twitter_post #CardioEd ...
DOI/PMID/ISBN: 10.1016/j.jchf.2024.08.007 [URL]( https://www.jacc.org/doi/full/10.1016/j.jchf.2024.08.007 ) Thank you in advance!
... jacc.org/doi/10.1016/j.jacc. 2025.02.018 #Cardiology #FOAMed #MedEd ... 2024.08.007?utm_medium=social&utm_source=twitt ...
https://www.jacc.org/doi/10.1016/j.jchf. 2024.08.007?utm_medium=social&utm_source=twitt er_post&utm_campaign=twitter_post #CardioEd # ...
https://www.jacc.org/doi/10.1016/j.jacc.2024.08.007. Válaszd a trial-t. Jó tanulmány, nyílt forráskódú, ajánlom, hogy nézz rá. "A COVID-19 ...
https://www.jacc.org/doi/10.1016/j.jacc.2024.08.007. SELECT denemesi. Güzel bir çalışma, açık kaynak, bir göz atmayı tavsiye ederim. "SELECT ...
https://www.jacc.org/doi/10.1016/j.jacc.2024.08.007. SELECT trial. Nice study, open source, recommend giving it a look. "The response to the ...
https://www.jacc.org/doi/10.1016/j.jacc.2024.08.007. SELECT исследование. Хорошее исследование, с открытым исходным кодом, рекомендую ...
https://www.jacc.org/doi/10.1016/j.jchf. 2024.08.007?utm_medium=social&utm_source=twitt er_post&utm_campaign=twitter_post #CardioEd ...
https://www.jacc.org/doi/10.1016/j.jchf. 2024.08.007?utm_medium=social&utm_source=twitt er_post&utm_campaign=twitter_post #CardioEd ...
... jacc.org/doi/10.1016/j.jacc.2024.08.007 (this is acute rather than Long COVID, and they don't report relative risk of LC in these two ...
https://www.jacc.org/doi/10.1016/j.jacc.2024.08.007 https://www.medpagetoday. com/meetingcoverage/esc/111720 https://www.nytimes. com ...
... health/wegovy-covid-deaths.html · https://www.jacc.org/doi/10.1016/j.jacc.2024.08.007 · Avatar för u/Livid-Economy-917 · Livid-Economy- ...
J Am Coll Cardiol. Published online August 27, 2024. doi:10.1016/j.jacc.2024.08.007; Brigham-Led Study Finds Weight Loss Drug Semaglutide ...
... nytimes.com/2024/08/30/health/wegovy-covid-deaths.html · https://www.jacc.org/doi/10.1016/j.jacc.2024.08.007 · Livid-Economy-917. • 1y ago.
DOI: https://doi.org/10.1016/j.jchf.2024.08.007 URL: https://www.jacc.org/doi/10.1016/j.jchf.2024.08.007.
... www.nytimes.com/2024/08/30/health/wegovy-covid-deaths.html · https://www.jacc.org/doi/10.1016/j.jacc.2024.08.007 · Livid-Economy-917. • 1年前.
Journal of the American College of Cardiology, 2024, DOI: 10.1016/j.jacc.2024.08.007, https://www.sciencedirect.com/science/article/pii ...
Hypotesskapande analyser av en omtalad studie indikerar att det aptitminskande läkemedlet Wegovy (semaglutid) skyddar mot dödsfall i ...
... (JACC)« publiziert wurde, konnte darüber hinaus zeigen, dass die ... DOI: 10.1016/j.jacc.2024.08.007. loading... Frag die KI. Die ...
jacc.org/doi/10.1016/j.jacc.2024.08.007 SELECT（RCT, 肥胖BMI ≥ 27、有心血管疾病、無糖尿病，平均治療34 個月，其中有n=17604）的二次分析發現 ...
... JACC Journals - Journals of the American College of ... https://www.jacc.org/doi/10.1016/j.jacc.2024.08.007 https://www.medpagetoday.
... J., & Ryan, D. (2024). The Effect of Semaglutide on Mortality and COVID ... https://doi.org/10.1016/j.jacc.2024.08.007 · Request Reprint ...
307 votes, 174 comments. https://www.jacc.org/doi/10.1016/j.jacc.2024.08.007 Kesimpulan Berbanding dengan plasebo, pesakit yang dirawat ...
2024;doi:10.1016/j.jacc.2024.08.007. Perspective. Back to Top. Harlan M. Krumholz, MD, SM, FACC.
... J Am Coll Cardiol 2024; DOI: 10.1016/j.jacc.2024.08.007. Secondary Source. Journal of the American College of Cardiology. Source Reference ...
doi.org/10.1016/j.jacc.2024.08.007. Be the first to rate this article. Posted in: Medical Research News | Medical Condition News | Healthcare ...
... jacc.org/doi/10.1016/j.jacc.2024.08.007. Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to ...
307 votes, 174 comments. https://www.jacc.org/doi/10.1016/j.jacc.2024.08.007 Conclusions Compared to placebo, patients treated with ...
307 votes, 174 comments. https://www.jacc.org/doi/10.1016/j.jacc.2024.08.007 Sonuçlar Plaseboya kıyasla, 2.4 mg semaglutid ile tedavi ...
https://www.jacc.org/doi/10.1016/j.jchf. 2024.08.007?utm_medium=social&utm_source=twitt er_post&utm_campaign=twitter_post #CardioEd # ...
https://www.jacc.org/doi/10.1016/j.jchf. 2024.08.007?utm_medium=social&utm_source=twitt er_post&utm_campaign=twitter_post #CardioEd # ...
... jacc.org/doi/10.1016/j.jacc. 2025.02.018 #Cardiology #FOAMed #MedEd ... 2024.08.007?utm_medium=social&utm_source=twitt ...
https://www.jacc.org/doi/10.1016/j.jacc.2024.08.007 https://www.medpagetoday. com/meetingcoverage/esc/111720 https://www.nytimes. com ...
https://www.jacc.org/doi/10.1016/j.jchf. 2024.08.007?utm_medium=social&utm_source=twitt er_post&utm_campaign=twitter_post #CardioEd # ...
... (JACC, 2024). No photo description available. Amro Alhadi ... https://www.jacc.org/doi/10.1016/j.jacc.2024.08.007 https://www.medpagetoday.
https://www.jacc.org/doi/10.1016/j.jchf. 2024.08.007?utm_medium=social&utm_source=twitt er_post&utm_campaign=twitter_post #CardioEd # ...
https://www.jacc.org/doi/10.1016/j.jchf. 2024.08.007?utm_medium=social&utm_source=twitt er_post&utm_campaign=twitter_post #CardioEd # ...
https://www.jacc.org/doi/10.1016/j.jchf. 2024.08.007?utm_medium=social&utm_source=twitt er_post&utm_campaign=twitter_post #CardioEd ...
Ayrıca bu hastalar koroner iskemi veya glokom vb nedenlerle beta blokerler, diltizem veya timolol gibi beta bloker özelliği olan göz damlası ...
31 likes, 0 comments - prof.dr.huseyinoflaz on July 5, 2022: "Koronerinizde atipik veya asemptomatik iken BT anjıo vb ile koronerlerde ...
https://www.jacc.org/doi/10.1016/j.jchf. 2024.08.007?utm_medium=social&utm_source=twitt er_post&utm_campaign=twitter_post #CardioEd # ...
53 likes, 0 comments - prof.dr.huseyinoflaz on May 4, 2022: "ESC 2021 ateroskleroz önleme guideline Kanser sıklığı arttı.
Yani hızlanmış ateroksleroz var. Ve muhtemel sebep olarak ICIs inh kullanımına bağlı Cx arterde daha önce var olan kritik olmayan yani %50'den ...
https://www.jacc.org/doi/10.1016/j.jchf. 2024.08.007?utm_medium=social&utm_source=twitt er_post&utm_campaign=twitter_post #CardioEd # ...
Her bolusun ardından 5-10 cc izotonik bolus atropin yapılan damardan verilmeliki atropin kana hızlı karışsın. Özellikle ventriküler ritm ...
https://www.jacc.org/doi/10.1016/j.jchf. 2024.08.007?utm_medium=social&utm_source=twitt er_post&utm_campaign=twitter_post #CardioEd ...
SI
JJ
SL
M無
AC
L
HN
JG
RF
AM
D
SF
JD
RL
JG
JS
R
DB
JP
JR
RA
CF
CM
MG
A
AM
JP
JT
DS
MM
JM
DJ
ZW
D
MB
GR
JM
CT
MP
NN
H
JJ
DP
J
L
HE
SC
A
C
I
МК
DP
SH
DZ
BR
H
H
P
ま
DP
れΕ
フ
CA
GR
TS
KM
VV
AG
DO
森
PC
S
AU
I
PL
CP
G
A
RM
NM
LB
GW
JJ
PS
LD
TP
K
TM
KF
JS
SR
AW
LK
DS
TA
JB
NM
?
JF
CD
JM
LS
AF
PA
JW
AA
JV
JB
ME
DL
KM
JM
SM
TG